JP2018527287A - ドセタキセルおよびヒト血清アルブミンの複合体 - Google Patents

ドセタキセルおよびヒト血清アルブミンの複合体 Download PDF

Info

Publication number
JP2018527287A
JP2018527287A JP2017560611A JP2017560611A JP2018527287A JP 2018527287 A JP2018527287 A JP 2018527287A JP 2017560611 A JP2017560611 A JP 2017560611A JP 2017560611 A JP2017560611 A JP 2017560611A JP 2018527287 A JP2018527287 A JP 2018527287A
Authority
JP
Japan
Prior art keywords
composition
serum albumin
docetaxel
human serum
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527287A5 (enExample
Inventor
サン，クイン
Original Assignee
アルブヴェックス エルエルシー
アルブヴェックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルブヴェックス エルエルシー, アルブヴェックス エルエルシー filed Critical アルブヴェックス エルエルシー
Publication of JP2018527287A publication Critical patent/JP2018527287A/ja
Publication of JP2018527287A5 publication Critical patent/JP2018527287A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017560611A 2015-05-15 2016-05-16 ドセタキセルおよびヒト血清アルブミンの複合体 Pending JP2018527287A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562162545P 2015-05-15 2015-05-15
US62/162,545 2015-05-15
US201562209053P 2015-08-24 2015-08-24
US62/209,053 2015-08-24
US201662299209P 2016-02-24 2016-02-24
US62/299,209 2016-02-24
PCT/US2016/032760 WO2016187147A1 (en) 2015-05-15 2016-05-16 Docetaxel and human serum albumin complexes

Publications (2)

Publication Number Publication Date
JP2018527287A true JP2018527287A (ja) 2018-09-20
JP2018527287A5 JP2018527287A5 (enExample) 2019-06-20

Family

ID=57320749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560611A Pending JP2018527287A (ja) 2015-05-15 2016-05-16 ドセタキセルおよびヒト血清アルブミンの複合体

Country Status (5)

Country Link
US (2) US10500285B2 (enExample)
EP (1) EP3294286A4 (enExample)
JP (1) JP2018527287A (enExample)
CN (2) CN107683134B (enExample)
WO (1) WO2016187147A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022503696A (ja) * 2018-10-17 2022-01-12 サンステイト バイオサイエンシーズ， エルエルシー 治療効果を高めるために単一タンパク質でカプセル化された医薬品
JP2023513524A (ja) * 2020-02-04 2023-03-31 珠海貝海生物技術有限公司 ドセタキセル製剤
JP2025506788A (ja) * 2022-02-25 2025-03-13 珠海貝海生物技術有限公司 ドセタキセル組成物及び方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294286A4 (en) * 2015-05-15 2019-01-02 Albuvex LLC Docetaxel and human serum albumin complexes
US20210386741A1 (en) * 2016-08-19 2021-12-16 Zhuhai Beihai Biotech Co., Ltd. Formulations of ibrutinib
CN110062622B (zh) 2016-10-27 2022-10-14 珠海贝海生物技术有限公司 多西他赛和人血清白蛋白的中性pH组合物
WO2018204386A1 (en) * 2017-05-01 2018-11-08 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
WO2019200084A1 (en) * 2018-04-11 2019-10-17 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
CN115400115B (zh) * 2021-05-26 2025-01-14 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
CN113577267B (zh) * 2021-09-06 2022-04-08 江西北正干细胞生物科技有限公司 Nk细胞和抗体的药物组合物及其在治疗癌症中的用途
CN119055767A (zh) * 2023-05-09 2024-12-03 上海津曼特生物科技有限公司 包含抗her2双特异性抗体的联合治疗药物及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
JP2003063960A (ja) * 1996-03-12 2003-03-05 Pg-Txl Co Lp 水溶性パクリタキセルプロドラッグ
US20050282734A1 (en) * 1998-07-30 2005-12-22 Kadima Tenshuk A Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP2008514720A (ja) * 2004-09-28 2008-05-08 エスディー ファーマシューティカルズ インコーポレイティッド タキソイドおよび他の不溶性薬物を送達するための低油乳剤組成物
CN101357126A (zh) * 2008-08-11 2009-02-04 张文芳 一种稳定的紫杉烷类白蛋白脂质载药系统及其制备方法
CN101361731A (zh) * 2008-08-11 2009-02-11 张文芳 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用
CN101658516A (zh) * 2008-08-26 2010-03-03 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
CN102688200A (zh) * 2012-05-09 2012-09-26 刘锋 植物类抗癌靶向纳米制剂及其制备方法
JP2013536805A (ja) * 2010-09-01 2013-09-26 北京大学 難溶性薬物の液体組成物及びその調製方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2007044950A2 (en) 2005-10-12 2007-04-19 Sicor, Inc. Crystalline forms of docetaxel and processes for their preparation
KR20080100264A (ko) 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
JP2010506932A (ja) 2006-10-20 2010-03-04 シノファーム シンガポール ピーティーイー，リミテッド 結晶性の無水ドセタキセルの製造方法
WO2008102374A1 (en) 2007-02-20 2008-08-28 Dabur Pharma Limited Amorphous form of docetaxel
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
EP2173732A4 (en) 2007-07-04 2011-09-07 Reddys Lab Ltd Dr PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC
CZ303072B6 (cs) 2009-02-13 2012-03-21 Zentiva, K.S. Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika
KR101149600B1 (ko) 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
US9333189B2 (en) * 2010-02-03 2016-05-10 Oncbiomune, Inc. Taxane- and taxoid-protein compositions
US10660965B2 (en) * 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
US8890233B2 (en) 2010-07-06 2014-11-18 Macronix International Co., Ltd. 3D memory array with improved SSL and BL contact layout
KR20120096200A (ko) 2011-02-22 2012-08-30 동아제약주식회사 결정형 도세탁셀 및 이의 제조방법
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
EP3294286A4 (en) 2015-05-15 2019-01-02 Albuvex LLC Docetaxel and human serum albumin complexes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
JP2003063960A (ja) * 1996-03-12 2003-03-05 Pg-Txl Co Lp 水溶性パクリタキセルプロドラッグ
US20050282734A1 (en) * 1998-07-30 2005-12-22 Kadima Tenshuk A Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP2008514720A (ja) * 2004-09-28 2008-05-08 エスディー ファーマシューティカルズ インコーポレイティッド タキソイドおよび他の不溶性薬物を送達するための低油乳剤組成物
CN101357126A (zh) * 2008-08-11 2009-02-04 张文芳 一种稳定的紫杉烷类白蛋白脂质载药系统及其制备方法
CN101361731A (zh) * 2008-08-11 2009-02-11 张文芳 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用
CN101658516A (zh) * 2008-08-26 2010-03-03 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
JP2013536805A (ja) * 2010-09-01 2013-09-26 北京大学 難溶性薬物の液体組成物及びその調製方法
CN102688200A (zh) * 2012-05-09 2012-09-26 刘锋 植物类抗癌靶向纳米制剂及其制备方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022503696A (ja) * 2018-10-17 2022-01-12 サンステイト バイオサイエンシーズ， エルエルシー 治療効果を高めるために単一タンパク質でカプセル化された医薬品
JP7573878B2 (ja) 2018-10-17 2024-10-28 サンステイト バイオサイエンシーズ， エルエルシー 治療効果を高めるために単一タンパク質でカプセル化された医薬品
JP2023513524A (ja) * 2020-02-04 2023-03-31 珠海貝海生物技術有限公司 ドセタキセル製剤
JP7734677B2 (ja) 2020-02-04 2025-09-05 珠海貝海生物技術有限公司 ドセタキセル製剤
JP2025506788A (ja) * 2022-02-25 2025-03-13 珠海貝海生物技術有限公司 ドセタキセル組成物及び方法

Also Published As

Publication number Publication date
CN112807299A (zh) 2021-05-18
WO2016187147A1 (en) 2016-11-24
US10500285B2 (en) 2019-12-10
US10780172B2 (en) 2020-09-22
EP3294286A1 (en) 2018-03-21
CN112807299B (zh) 2022-06-24
CN107683134A (zh) 2018-02-09
US20180289818A1 (en) 2018-10-11
US20200061194A1 (en) 2020-02-27
CN107683134B (zh) 2021-02-23
EP3294286A4 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
US10780172B2 (en) Docetaxel and human serum albumin complexes
US12128022B2 (en) Neutral pH compositions of docetaxel and human serum albumin
US11510895B2 (en) Compositions and formulations including cabazitaxel and human serum albumin
CN109922790B (zh) 卡博替尼制剂
CN112055588B (zh) 卡巴他赛的制剂和组合物
US20240189272A1 (en) Formulations and compositions of docetaxel
CN116747217B (zh) 多西他赛制剂和组合物
CN109715213B (zh) 依鲁替尼制剂
HK40085284A (en) Neutral ph compositions of docetaxel and human serum albumin
HK40085284B (zh) 多西他赛和人血清白蛋白的中性ph组合物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201